Latest by Canadian AIDS Treatment Information Exchange
Doctors in Toronto did something novel: They prescribed post-exposure prophylaxis (PEP) in advance so that in case of potential exposure patients can initiate PEP on their own and then subsequently seek medical attention.
As more people start HIV treatment, researchers are exploring ways to cut costs. Single tablets can be replaced by a few pills comprising cheaper generic drugs.
An examination of what we know about the risk of passing HIV through pregnancy, childbirth, and infant feeding.
Researchers found that people taking common combinations of HIV drugs had increases in weight and body mass index, and those who were relatively thin or older prior to starting therapy were most likely to gain weight.
Researchers found that a large proportion of men felt the need to conceal their use of PrEP from friends, family and sexual partners because of attitudes toward PrEP use.
A one-year clinical trial has found that this potent statin can help to normalize cholesterol levels in HIV-positive people.
Researchers tested a single injection of the antibody canakinumab in HIV-positive people taking antiretroviral therapy and found that the drug significantly reduced inflammation and did not cause harm, at least in the short term.
Researchers found that inflammation in the arteries of HIV-positive people was "modestly increased" and that the level of inflammation in the lymph nodes was generally higher than in the arteries.
Researchers have found that having an elevated level of a protein that is released into the blood of people during chronic inflammation was linked to an increased risk for subsequent serious health problems as well as diminished survival.
Chronic HIV infection is associated with relatively high levels of inflammation and a growing body of evidence suggests that inflammation may increase the risk for a range of health problems.